Literature DB >> 19948831

Endometrial cells get side-tracked: side population cells promote epithelial-mesenchymal transition in endometrial carcinoma.

Martin Götte1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19948831      PMCID： PMC2797865          DOI： 10.2353/ajpath.2010.090775

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  22 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues.

Authors:  S Kyo; T Kanaya; M Takakura; M Tanaka; M Inoue
Journal:  Int J Cancer       Date:  1999-01-05       Impact factor: 7.396

Review 3.  Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications.

Authors:  Stanley J Miller; Robert M Lavker; Tung-Tien Sun
Journal:  Biochim Biophys Acta       Date:  2005-09-25

4.  Abnormalities of the APC/beta-catenin pathway in endometrial cancer.

Authors:  Gema Moreno-Bueno; David Hardisson; Carolina Sánchez; David Sarrió; Raúl Cassia; Ginesa García-Rostán; Jaime Prat; Mingzhou Guo; James G Herman; Xavier Matías-Guiu; Manel Esteller; José Palacios
Journal:  Oncogene       Date:  2002-11-14       Impact factor: 9.867

Review 5.  Therapeutic value of glycosaminoglycans in cancer.

Authors:  George W Yip; Martin Smollich; Martin Götte
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

6.  Oct-4 expression in human endometrium.

Authors:  C Matthai; R Horvat; M Noe; F Nagele; A Radjabi; M van Trotsenburg; J Huber; A Kolbus
Journal:  Mol Hum Reprod       Date:  2006-01-18       Impact factor: 4.025

7.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Authors:  S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

8.  The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.

Authors:  Chunxiao Zhou; Victoria L Bae-Jump; Young E Whang; Paola A Gehrig; John F Boggess
Journal:  Gynecol Oncol       Date:  2005-12-27       Impact factor: 5.482

9.  Prognostic significance of syndecan-1 expression in human endometrial cancer.

Authors:  J Kodama; T Kusumoto; Y Shinyo; N Seki; Y Hiramatsu
Journal:  Ann Oncol       Date:  2005-04-22       Impact factor: 32.976

10.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728
View more
  5 in total

Review 1.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  mRNA-expression of ERα, ERβ, and PR in clonal stem cell cultures obtained from human endometrial biopsies.

Authors:  A N Schüring; J Braun; S Wüllner; L Kiesel; M Götte
Journal:  ScientificWorldJournal       Date:  2011-10-18

3.  Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.

Authors:  Sherif A Ibrahim; Hebatallah Hassan; Laura Vilardo; Sampath Katakam Kumar; Archana Vijaya Kumar; Reinhard Kelsch; Cornelia Schneider; Ludwig Kiesel; Hans Theodor Eich; Ileana Zucchi; Rolland Reinbold; Burkhard Greve; Martin Götte
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

4.  Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.

Authors:  Sherif Abdelaziz Ibrahim; Ramy Gadalla; Eslam A El-Ghonaimy; Omnia Samir; Hossam Taha Mohamed; Hebatallah Hassan; Burkhard Greve; Mohamed El-Shinawi; Mona Mostafa Mohamed; Martin Götte
Journal:  Mol Cancer       Date:  2017-03-07       Impact factor: 27.401

5.  MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch1 in endometrial cancer.

Authors:  Zhen Wang; Wei Wang; Kangrong Huang; Yueling Wang; Jing Li; Xinyuan Yang
Journal:  Oncotarget       Date:  2017-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.